arrow
B

Britta Weigelt

Memorial Sloan Kettering Cancer Center
H指数:97
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment

生殖系同源重组缺陷影响铂类和PARP抑制剂治疗期间TP53突变克隆性造血的适应性

2026-09-280
OAAI
Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study

极低碳水化合物生酮饮食在初治未接受过治疗的子宫内膜癌伴超重女性中的随机可行性研究

2026-05-270
OAAI
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

乳腺癌的同源重组缺陷和半合子驱动抵抗

Nature
IF48.5
2026-03-040
OAAI
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer

出版商更正:APOBEC3突变驱动乳腺癌的疗法抵抗

2025-12-120
OAAI
Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology

实现从FFPE标本在临床肿瘤学中进行全基因组测序分析

2025-11-270
OAAI
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer

一项关于尼洛替尼与卵巢癌新诊断患者新辅助及术后化疗联合应用的试点研究

2025-10-310
PRE
Prognostic value of positive peritoneal cytology in FIGO 2009 stage IA grade 1 endometrioid endometrial cancer

FIGO 2009分期标准下,G1级子宫内膜样子宫内膜癌中阳性腹水细胞学的预后价值

2025-10-170
PRE
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA

使用细胞游离DNA追踪卵巢癌治疗过程中的克隆进化

Nature
IF48.5
2025-10-010
OA
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

正在进行的基因组加倍塑造卵巢癌的进化和免疫力

Nature
IF48.5
2025-07-160
OA
Genomic landscape of breast cancer in elderly patients

老年乳腺癌患者的基因组景观

2025-07-100
OAAI
Comprehensive Molecular, Pathological, and Clinical Characterization of Clear Cell Adenocarcinoma of the Urinary Tract

尿路上皮透明细胞腺癌的全面分子、病理学和临床特征分析

2025-06-180
PRE
APOBEC3 mutagenesis drives therapy resistance in breast cancer

APOBEC3诱变驱动乳腺癌的疗法抗性。

2025-05-160
OA
Evolution of tumor stress response during cytoreductive surgery for ovarian cancer

卵巢癌细胞减灭术期间肿瘤应激反应的演变

2025-05-010
OAAI
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate

晚期卵巢癌患者接受抗FOLR1抗体药物偶联物治疗后的临床结局

2025-04-010
PRE